Spots Global Cancer Trial Database for dipg
Every month we try and update this database with for dipg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | NCT03355794 | Diffuse Intrins... Malignant Gliom... High Grade Glio... Bithalamic High... Brainstem Gliom... Glioblastoma Anaplastic Astr... | ribociclib Everolimus | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | NCT03330197 | Pediatric Brain... Diffuse Intrins... | Ad-RTS-hIL-12 Oral Veledimex ... Oral Veledimex ... | 0 Years - 21 Years | Alaunos Therapeutics | |
| xPedite: A Study to Expedite DIPG and DMG Research | NCT06140719 | Oncology DIPG DMG | - | xCures | ||
| A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors | NCT03967093 | Neoplasms | BXQ-350 | 1 Year - 30 Years | Bexion Pharmaceuticals, Inc. | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | NCT04295759 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... DIPG High-grade Astr... CNS Primary Tum... | INCB7839 | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma | NCT04250064 | DIPG | Bevacizumab Inj... Ultra-low-dose ... | 3 Years - 18 Years | Tata Memorial Centre | |
| A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas | NCT04808245 | Newly Diagnosed... | Tecentriq 1200 ... H3K27M peptide ... Imiquimod (5%) | 18 Years - | German Cancer Research Center | |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | NCT04943848 | Diffuse Intrins... Diffuse Midline... | rHSC-DIPGVax Balstilimab Zalifrelimab | 12 Months - 18 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | NCT01837862 | Pilomyxoid Astr... Pilocytic Astro... Glioma, Astrocy... Optic Nerve Gli... Pleomorphic Xan... Glioblastoma Mu... Anaplastic Astr... Gliosarcoma Diffuse Intrins... DIPG Low-grade Gliom... Brainstem Gliom... | Mebendazole Vincristine Carboplatin Temozolomide Bevacizumab Irinotecan | 1 Year - 21 Years | Northwell Health | |
| Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children | NCT01635140 | Pediatric Brain... | Hypofractionate... Conventional ar... | 3 Years - 18 Years | Children's Cancer Hospital Egypt 57357 | |
| Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) | NCT01469247 | Brain Cancer | Radiation Thera... | - 17 Years | M.D. Anderson Cancer Center | |
| International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) | NCT03243461 | Glioblastoma WH... Diffuse Midline... Anaplastic Astr... Diffuse Intrins... Gliomatosis Cer... | Temozolomide + ... | 3 Years - 17 Years | University of Göttingen | |
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | NCT05768880 | Diffuse Intrins... Diffuse Midline... Recurrent CNS T... Recurrent, CNS ... Refractory Prim... | SC-CAR4BRAIN | 1 Year - 26 Years | Seattle Children's Hospital | |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | NCT05630209 | Brain Tumor | Exablate Doxorubicin | 5 Years - 21 Years | InSightec | |
| Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children | NCT01635140 | Pediatric Brain... | Hypofractionate... Conventional ar... | 3 Years - 18 Years | Children's Cancer Hospital Egypt 57357 | |
| 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | NCT05063357 | DIPG | 131I-Omburtamab Convention Enha... | 3 Years - 21 Years | Y-mAbs Therapeutics | |
| Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | NCT01106794 | Diffuse Intrins... Brainstem Gliom... | - 21 Years | Children's National Research Institute | ||
| A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) | NCT04771897 | Diffuse Intrins... Diffuse Midline... | BXQ-350 - Part ... BXQ-350 - Part ... | 1 Year - 30 Years | Bexion Pharmaceuticals, Inc. | |
| A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | NCT02607124 | High Grade Glio... Diffuse Intrins... Bithalamic High... | Ribociclib | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | NCT02960230 | Diffuse Intrins... Glioma Diffuse Midline... | K27M peptide Nivolumab | 3 Years - 21 Years | University of California, San Francisco | |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | NCT02758366 | Glioblastoma (G... DIPG Brainstem Gliom... Diffuse Spinal ... Bilateral Thala... Gliomatosis Cer... Anaplastic Astr... Midline Diffuse... | Doxorubicin | 3 Years - 30 Years | Meyer Children's Hospital IRCCS | |
| Immune Modulatory DC Vaccine Against Brain Tumor | NCT03914768 | Diffuse Intrins... | Immunomodulator... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | NCT03330197 | Pediatric Brain... Diffuse Intrins... | Ad-RTS-hIL-12 Oral Veledimex ... Oral Veledimex ... | 0 Years - 21 Years | Alaunos Therapeutics | |
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | NCT05768880 | Diffuse Intrins... Diffuse Midline... Recurrent CNS T... Recurrent, CNS ... Refractory Prim... | SC-CAR4BRAIN | 1 Year - 26 Years | Seattle Children's Hospital | |
| Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma | NCT01774253 | Pontine Glioma | Vismodegib | 3 Years - 18 Years | Milton S. Hershey Medical Center | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG | NCT06221553 | DIPG Brain Tumo... Diffuse Intrins... | B7H3 specific C... | 1 Year - 18 Years | Chulalongkorn University | |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | NCT02960230 | Diffuse Intrins... Glioma Diffuse Midline... | K27M peptide Nivolumab | 3 Years - 21 Years | University of California, San Francisco | |
| A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | NCT03632317 | Glioma Diffuse Intrins... | Panobinostat Everolimus | 2 Years - 30 Years | University of Michigan Rogel Cancer Center | |
| A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | NCT03257631 | Central Nervous... Medulloblastoma | Pomalidomide Pomalidomide | 1 Year - 21 Years | Celgene | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children | NCT01635140 | Pediatric Brain... | Hypofractionate... Conventional ar... | 3 Years - 18 Years | Children's Cancer Hospital Egypt 57357 | |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | NCT02758366 | Glioblastoma (G... DIPG Brainstem Gliom... Diffuse Spinal ... Bilateral Thala... Gliomatosis Cer... Anaplastic Astr... Midline Diffuse... | Doxorubicin | 3 Years - 30 Years | Meyer Children's Hospital IRCCS | |
| 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma | NCT05063357 | DIPG | 131I-Omburtamab Convention Enha... | 3 Years - 21 Years | Y-mAbs Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
